Crohn's disease

G Roda, S Chien Ng, PG Kotze, M Argollo… - Nature Reviews …, 2020 - nature.com
Crohn's disease is an inflammatory bowel disease that is characterized by chronic
inflammation of any part of the gastrointestinal tract, has a progressive and destructive …

[HTML][HTML] γδ T cells: origin and fate, subsets, diseases and immunotherapy

Y Hu, Q Hu, Y Li, L Lu, Z Xiang, Z Yin… - … and Targeted Therapy, 2023 - nature.com
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon

L Kong, V Pokatayev, A Lefkovith, GT Carter… - Immunity, 2023 - cell.com
Crohn's disease (CD) is a chronic gastrointestinal disease that is increasing in prevalence
worldwide. CD is multifactorial, involving the complex interplay of genetic, immune, and …

Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries

Z Liu, R Liu, H Gao, S Jung, X Gao, R Sun, X Liu… - Nature …, 2023 - nature.com
Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract with
the following two subtypes: Crohn's disease (CD) and ulcerative colitis (UC). To date, most …

Targeting immune cell circuits and trafficking in inflammatory bowel disease

MF Neurath - Nature immunology, 2019 - nature.com
Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are
characterized by uncontrolled activation of intestinal immune cells in a genetically …

[HTML][HTML] The gut microbiome and inflammatory bowel diseases

Y Shan, M Lee, EB Chang - Annual review of medicine, 2022 - annualreviews.org
Inflammatory bowel diseases (IBD) arise from a convergence of genetic risk, environmental
factors, and gut microbiota, where each is necessary but not sufficient to cause disease …

[HTML][HTML] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses

J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - …, 2023 - thelancet.com
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …

[HTML][HTML] Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes

DM Ruderfer, S Ripke, A McQuillin, J Boocock… - Cell, 2018 - cell.com
Schizophrenia and bipolar disorder are two distinct diagnoses that share symptomology.
Understanding the genetic factors contributing to the shared and disorder-specific symptoms …

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management

M Harbord, R Eliakim, D Bettenworth… - Journal of Crohn's …, 2017 - academic.oup.com
11.1. General The treatment strategy for ulcerative colitis [UC] is mainly based on the
severity, distribution [proctitis, left-sided, extensive] 1 and pattern of disease. The latter …

IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting

AR Moschen, H Tilg, T Raine - Nature Reviews Gastroenterology & …, 2019 - nature.com
Abstract IL-12 and IL-23 are closely related cytokines with important roles in the regulation of
tissue inflammation. Converging evidence from studies in mice, human observational …